53
Participants
Start Date
December 6, 2018
Primary Completion Date
January 8, 2021
Study Completion Date
December 30, 2022
AVB-S6-500
AVB-S6-500 is experimental drug
Paclitaxel (Pac)
Paclitaxel is active comparator
Pegylated liposomal doxorubicin (PLD)
PLD is active comparator
Placebo
Placebo comparator
Washington University, St Louis
OUHSC-Stephenson Cancer Center, Oklahoma City
Texas Oncology - Fort Worth, Fort Worth
Texas Oncology - San Antonio Medical Center, San Antonio
Texas Oncology - Austin Central, Austin
Arizona Oncology, Phoenix
Arizona Oncology Associates, Tucson
Kaiser Permanente San Francisco, San Francisco
Kaiser Permanente Vallejo, Vallejo
Kaiser Permanente Walnut Creek, Walnut Creek
Kaiser Permanente Oakland, Oakland
Kaiser Permanente Santa Clara, Santa Clara
Kaiser Permanente Roseville, Roseville
Willamette Valley Cancer Institute and Research Center, Eugene
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Aravive, Inc.
INDUSTRY